최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기KSBB Journal, v.25 no.4, 2010년, pp.319 - 329
박명수 (안양과학대학 호텔조리과) , 지근억 ((주)비피도 기술연구소)
Bifidobacteria comprises up to 25% of the cultivable fecal bacteria in adults and 80% in infants. Many in vivo and clinical research results supporting its efficacy in the prevention and improvement of gastrointestinal health have been accumulated. As a consequence, expert committee WHO/FAO expert c...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
비피더스균이란 무엇인가? | 비피더스균은 완전 혐기성균으로 무포자, 비운동성의 그람 양성 간균으로 종, 속 및 배양환경 등에 따라 다양한 형태학적인 특성을 보여준다. Tissier [1]에 의해 처음 유아의 장에서 관찰 된 이래 초기에는 Lactobacillaceae로 분류되었으나 (Lactobacillus bifidum) 1924년에 Orla Jensen이 Bifidobacterium으로 재 분류 하였고 1974년 the 8th Edition of Bergey’s Manual of Determinative Bacteriology에서부터 독립된 속으로 표기되었다. | |
비피더스균의 분류학상 위치는 어디인가? | Tissier [1]에 의해 처음 유아의 장에서 관찰 된 이래 초기에는 Lactobacillaceae로 분류되었으나 (Lactobacillus bifidum) 1924년에 Orla Jensen이 Bifidobacterium으로 재 분류 하였고 1974년 the 8th Edition of Bergey’s Manual of Determinative Bacteriology에서부터 독립된 속으로 표기되었다. 현재 Bifidobacteirum의 분류학상 위치는 Actinobacteria phylum (문), Actinobacteria class (강), Bifidobacteriales order (목), Bifidobacteria family (과), Bifidobacterium genus (속)로 분류되고 있다. 비피더스균의 분류에는 세포의 형태학적인 모습이나, 집락의 모양 및 당발효 특징, 영양요구 특성 발효대사산물 등에 의한 전통적인 분류와 16S rRNA 염기 조성, RAPD, FISH, pulsed field gel electrophoresis 등 유전자의 특성을 이용하는 분류 동정 방법이 많이 이용되고 있다 [2,3]. | |
프로바이오틱스란 무엇인가? | 장내에 Bifidobacterium 등의 유익균 이 감소하면 알레르기, 설사 및 기타 질병이 증가하는 것으로 알려져 있다. 이와 같은 Bifidobacterium 등의 유익균을 생균제로 섭취하였을 때 인체의 건강을 증진시키는 균을 프로바이오틱스라고 한다. 최근 프로바이오틱스 균주는 유아를 비롯한 인체의 알레르기 발생, 감염성 설사 및 염증 증상을 경감시키는 임상적 효과들이 많이 보고되고 있다. |
Tissier, H. (1900) Recherchers sur la flora intestinale normale et pathologique du nourisson. University of Paris, Paris.
Jian, W., L. Zhu, and X. Dong (2001) New approach to phylogenetic analysis of the genus Bifidobacterium based on partial HSP60 gene sequences. Int. J. Syst. Evol. Microbiol. 51: 1633-1638.
Ward, P. and D. Roy (2005) Review of molecular methods for identification, characterization and detection of bifidobacteria. Lait. 85: 23-32.
Satokari, R. M., E. E. Vaughan, H. Smidt, M. Saarela, J. Matto, and W. M. de Vos (2003) Molecular approaches for the detection and identification of bifidobacteria and lactobacilli in the human gastrointestinal tract. Syst. Appl. Microbiol. 26: 572-584.
Coeuret, V., M. Gueguen, and J. P. Vernoux (2004) Numbers and strains of lactobacilli in some probiotic products. Int. J. Food Microbiol. 97: 147-156.
Berg, R. D. (1996) The indigenous gastrointestinal microflora. Trends Microbiol. 4: 430-435.
Homma, N. (1998) Bifidobacteria as a resistance factor in human beings. Bifidobact. Microfl. 7: 35-43.
Berrada, N., J. F. Lemeland, G. Laroche, P. Thouvenot, and M. Piaia (1991) Bifidobacterium from fermented milks: survival during gastric transit. J. Dairy Sci. 74: 409-413.
Bezkorovainy, A. (2001) Probiotics: determinants of survival and growth in the gut. Am. J. Clin. Nutr. 73: 399S-405S.
Kim, N. J., S. J. Park, E. M. Yum, H. Y. Kim, S. H. Lee, J. H. Min, M. S. Park, and G. E. Ji (2003) Effect of Bifidobacterium-fermented soy hypocotyls intake on the composition of human large intestinal bacteria in the elderly. Food Sci. Biotechnol. 12: 178-179.
Kullen, M. J., M. M. Amann, M. J. O'Shaughnessy, D. J. O'Sullivan, F. F. Busta, and L. J. Brady (1997) Differentiation of ingested and endogenous bifidobacteria by DNA fingerprinting demonstrates the survival of an unmodified strain in the gastrointestinal tract of humans. J. Nutr. 127: 89-94.
Bouvier, M., S. Meance, C. Bouley, J. L. Berta, and J. C. Grimaud (2001) Effects of consumption of a milk fermented by the probiotic strain bifidobacterium animalis DN-173010 on colonic transit times in healthy humans. Biosci. Microflora. 20: 43-48.
Marteau, P., E. Cuillerier, S. Meance, M. F. Gerhardt, A. Myara, M. Bouvier, C. Bouley, F. Tondu, G. Bommelaer, and J. C. Grimaud (2002) Bifidobacterium animalisstrain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment. Pharmacol. Ther. 16: 587-593.
Meance, S., C. Cayuela, A. Raimondi, P. Turchet, C. Lucas, and A. J. M. (2003) Recent advances in the use of functional foods: effects of the commercial fermented milk with Bifidobacterium animalis strain DN-173 010 and yoghurt strains on gut transit time in the elderly. Microbial. Ecol. Health Disease 15: 15-22.
Lievin, V., I. Peiffer, S. Hudault, F. Rochat, D. Brassart, J. R. Neeser, and A. L. Servin (2000) Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut 47: 646-652.
Fujiwara, S., H. Hashiba, T. Hirota, and J. F. Forstner (1997) Proteinaceous factor(s) in culture supernatant fluids of bifidobacteria which prevents the binding of enterotoxigenic Escherichia coli to gangliotetraosylceramide. Appl. Environ. Microbiol. 63: 506-512.
Gagnon, M., E. E. Kheadr, G. Le Blay, and I. Fliss (2004) In vitro inhibition of Escherichia coli O157: H7 by bifidobacterial strains of human origin. Int. J. Food Microbiol. 92: 69-78.
Moroni, O., E. Kheadr, Y. Boutin, C. Lacroix, and I. Fliss (2006) Inactivation of adhesion and invasion of food-borne Listeria monocytogenes by bacteriocinproducing Bifidobacterium strains of human origin. Appl. Environ. Microbiol. 72: 6894-6901.
Lee, J. H., V. N. Karamychev, S. A. Kozyavkin, D. Mills, A. R. Pavlov, N. V. Pavlova, N. N. Polouchine, P. M. Richardson, V. V. Shakhova, A. I. Slesarev, B. Weimer, and D. J. O'Sullivan (2008) Comparative genomic analysis of the gut bacterium Bifidobacterium longum reveals loci susceptible to deletion during pure culture growth. BMC Genomics 9: 247.
Otte, J. M., E. Cario, and D. K. Podolsky (2004) Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology 126: 1054-1070.
Tanaka, K. and H. Ishikawa (2004) Role of intestinal bacterial flora in oral tolerance induction. Histol. Histopathol. 19: 907-914.
Sudo, N., S. Sawamura, K. Tanaka, Y. Aiba, C. Kubo, and Y. Koga (1997) The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction. J. Immunol. 159: 1739-1745.
Delneste, Y., A. Donnet-Hughes, and E. J. Schiffrin (1998) Functional foods: mechanisms of action on immunocompetent cells. Nutr. Rev. 56: S93-98.
Blum, S., S. Alvarez, D. Haller, P. Perez, and E. J. Schiffrin (1999) Intestinal microflora and the interaction with immunocompetent cells. Anton. Leeuw. 76: 199-205.
MacDonald, T. T., and S. Pettersson (2000) Bacterial regulation of intestinal immune responses. Inflamm. Bowel Dis. 6: 116-122.
Bjorksten, B., P. Naaber, E. Sepp, and M. Mikelsaar (1999) The intestinal microflora in allergic Estonian and Swedish 2-year-old children. Clin. Exp. Allergy 29: 342-346.
Bjorksten, B., E. Sepp, K. Julge, T. Voor, and M. Mikelsaar (2001) Allergy development and the intestinal microflora during the first year of life. J. Allergy Clin. Immunol. 108: 516-520.
Kalliomki, M., P. Kirjavainen, E. Eorola, P. Kero, S. Salminen, and E. Isolauri (2001) Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J. Allergy Clin. Immunol. 107: 129-134.
Watanabe, S., Y. Narisawa, S. Arase, H. Okamatsu, T. Ikenaga, and Y. Tagira (2003) Differences in fecal microflora between patients with atopic dermatitis and healthy control subjects. J. Allergy Clin. Immunol. 111: 587-591.
He, F., A. C. Ouwehand, E. Isolauri, H. Hashimoto, Y. Benno, and S. Salminen (2001) Comparison of mucosal adhesion and species identification of bifidobacteria isolated from healthy and allergic infants. FEMS Immunol. Med. Microbiol. 30: 43-47.
Sakata, H., H. Yoshioka, and K. Fujita (1985) Development of the intestinal flora in very low birth weight infants compared to normal full-term newborns. Eur. J. Pediatr. 144: 186-190.
Kitajima, H., Y. Sumida, R. Tanaka, N. Yuki, H. Takayama, and M. Fujimura (1997) Early administration of Bifidobacterium breve to preterm infants: randomised controlled trial. Arch. Dis. Child Fetal Neonatal Ed. 76: F101-107.
Lin, H. C., B. H. Su, A. C. Chen, T. W. Lin, C. H. Tsai, T. F. Yeh, and W. Oh (2005) Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants. Pediatrics 115: 1-4.
Bin-Nun, A., R. Bromiker, M. Wilschanski, M. Kaplan, B. Rudensky, M. Caplan, and C. Hammerman (2005) Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J. Pediatr. 147: 192-196.
Dani, C., R. Biadaioli, G. Bertini, E. Martelli, and F. F. Rubaltelli (2002) Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective doubleblind study. Biol. Neonate. 82: 103-108.
Weizman, Z., G. Asli, and A. Alsheikh (2005) Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 115: 5-9.
Thibault, H., C. Aubert-Jacquin, and O. Goulet (2004) Effects of long-term consumption of a fermented infant formula (with Bifidobacterium breve c50 and Streptococcus thermophilus 065) on acute diarrhea in healthy infants. J. Pediatr. Gastroenterol. Nutr. 39: 147-152.
Saavedra, J. M., A. Abi-Hanna, N. Moore, and R. H. Yolken (2004) Long-term consumption of infant formulas containing live probiotic bacteria: tolerance andsafety. Am. J. Clin. Nutr. 79: 261-267.
Allen, S. J., B. Okoko, E. G. Martinez, G. V. Gregorio, and L. F. Dans (2004) Probiotics for treating infectious diarrhoea. Cochrane Cochrane Database of Systematic Reviews. Art. No. CD003048.
Shin, K. M., J. Y. Byun, M. S. Park, G. E. Ji, and D. S. Kim (2003) Effect of Lactic acid bacteria on rotaviral enteritis. Proceedings of the annual meeting of The Korean Society of Food Service Sanitation. November 08, Seoul, Korea.
Sampson, H. A., L. Mendelson, and J. P. Rosen (1992) Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N. Engl. J. Med. 327: 380-384.
Ogura, Y., H. Ogura, and N. Zusi (2001) The incidence of food allergy in atopic dermatitis. Arerugi. 50: 621-628.
Lee, S. I., M. H. Shin, H. B. Lee, J. S. Lee, B. K. Son, Y. Y. Koh, K. E. Kim, and Y. O. Ahn (2001) Prevalences of symptoms of asthma and other allergic diseases in korean children: a nationwide questionnaire survey. J. Korean Med. Sci. 16: 155-164.
Flohr, C., D. Pascoe, and H. C. Williams (2005) Atopic dermatitis and the 'hygiene hypothesis': too clean to be true? Br. J. Dermatol. 152: 202-216.
Braun-Fahrlander, C., J. Riedler, U. Herz, W. Eder, M. Waser, L. Grize, S. Maisch, D. Carr, F. Gerlach, A. Bufe, R. P. Lauener, R. Schierl, H. Renz, D. Nowak, and E. von Mutius (2002) Environmental exposure to endotoxin and its relation to asthma in school-age children. N. Engl. J. Med. 347: 869-877.
Hansen, G., J. J. McIntire, V. P. Yeung, G. Berry, G. J. Thorbecke, L. Chen, R. H. DeKruyff, and D. T. Umetsu (2000) CD4 (+) T helper cells engineered to produce latent TGF-beta1 reverse allergen-induced airway hyperreactivity and inflammation. J. Clin. Invest. 105: 61-70.
Prescott, S. L. (2003) Allergy: the price we pay for cleaner living? Ann. Allergy Asthma Immunol. 90: 64-70.
Perez-Machado, M. A., P. Ashwood, M. A. Thomson, F. Latcham, R. Sim, J. A. Walker-Smith, and S. H. Murch (2003) Reduced transforming growth factor-beta1- producing T cells in the duodenal mucosa of children with food allergy. Eur. J. Immunol. 33: 2307-2315.
Teitelbaum, J. E. and W. A. Walker (2002) Nutritional impact of pre- and probiotics as protective gastrointestinal organisms. Annu. Rev. Nutr. 22: 107-138.
Hattori, K., A. Yamamoto, M. Sasai, S. Taniuchi, T. Kojima, Y. Kobayashi, H. Iwamoto, K. Namba, and T. Yaeshima (2003) Effects of administration of bifidobacteria on fecal microflora and clinical symptoms in infants with atopic dermatitis. Arerugi. 52: 20-30.
Isolauri, E., T. Arvola, Y. Sutas, E. Moilanen, and S. Salminen (2000) Probiotics in the management of atopic eczema. Clin. Exp. Allergy 30: 1604-1610.
Rosenfeldt, V., E. Benfeldt, S. D. Nielsen, K. F. Michaelsen, D. L. Jeppesen, N. H. Valerius, and A. Paerregaard (2003) Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J. Allergy Clin. Immunol. 111: 389-395.
Kim, H., K. Kwack, D. Y. Kim, and G. E. Ji (2005) Oral probiotic bacterial administration suppressed allergic responses in an ovalbumin-induced allergy mouse model. FEMS Immunol. Med. Microbiol. 45: 259-267.
Kim, H., S. Y. Lee, and G. E. Ji (2005) Timing of Bifidobacterium administration influences the development of allergy to ovalbumin in mice. Biotechnol. Lett. 27: 1361-1367.
Kim, J. Y., J. H. Kwon, S. H. Ahn, S. I. Lee, Y. S. Han, Y. O. Choi, S. Y. Lee, K. M. Ahn, and G. E. Ji (2010) Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial. Pediatr. Allergy Immunol. 21: e386-393.
Sgorbati, B., V. Scardovi, and D. J. Leblanc (1982) Plasmids in the genus Bifidobacterium. J. Gen. Microbiol. 128: 2121-2131.
Corneau, N., E. Emond, and G. LaPointe (2004) Molecular characterization of three plasmids from Bifidobacterium longum. Plasmid 51: 87-100.
Guglielmetti, S., M. Karp, D. Mora, I. Tamagnini, and C. Parini (2007) Molecular characterization of Bifidobacterium longum biovar longum NAL8 plasmids and construction of a novel replicon screening system. Appl. Microbiol. Biotechnol. 74: 1053-1061.
Lee, J. H. and D. J. O'Sullivan (2006) Sequence analysis of two cryptic plasmids from Bifidobacterium longum DJO10A and construction of a shuttle cloning vector. Appl. Environ. Microbiol. 72: 527-535.
O'Riordan, K. and G. F. Fitzgerald (1999) Molecular characterisation of a 5.75-kb cryptic plasmid from Bifidobacterium breve NCFB 2258 and determination of mode of replication. FEMS Microbiol. Lett. 174: 285-294.
Park, M. S., D. W. Shin, K. H. Lee, and G. E. Ji (1999) Sequence analysis of plasmid pKJ50 from Bifidobacterium longum. Microbiology 145: 585-592.
Sangrador-Vegas, A., C. Stanton, D. van Sinderen, G. F. Fitzgerald, and R. P. Ross (2007) Characterization of plasmid pASV479 from Bifidobacterium pseudolongum subsp. globosum and its use for expression vector construction. Plasmid 58: 140-147.
Tanaka, K., K. Samura, and Y. Kano (2005) Structural and functional analysis of pTB6 from Bifidobacterium longum. Biosci. Biotechnol. Biochem. 69: 422-425.
Moon, G. S., Y. R. Pyun, M. S. Park, G. E. Ji, and W. J. Kim (2005) Secretion of recombinant pediocin PA-1 by Bifidobacterium longum, using the signal sequence for bifidobacterial alpha-amylase. Appl. Environ. Microbiol. 71: 5630-5632.
Park, M. S., J. M. Seo, J. Y. Kim, and G. E. Ji (2005) Heterologous gene expression and secretion in Bifidobacterium longum. Lait 85: 1-8.
Rossi, M., P. Brigidi, and D. Matteuzzi (1998) Improved cloning vectors for Bifidobacterium spp. Lett. Appl. Microbiol. 26: 101-104.
Park, M. S., B. Kwon, J. J. Shim, C. S. Huh, and G. E. Ji (2008) Heterologous expression of cholesterol oxidase in Bifidobacterium longumunder the control of 16S rRNA gene promoter of bifidobacteria. Biotechnol. Lett. 30: 165-172.
Yazawa, K., M. Fujimori, J. Amano, Y. Kano, and S. Taniguchi (2000) Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors. Cancer Gene Ther. 7: 269-274.
Fujimori, M. (2006) Genetically engineered bifidobacterium as a drug delivery system for systemic therapy of metastatic breast cancer patients. Breast Cancer 13: 27-31.
Yi, C., Y. Huang, Z. Y. Guo, and S. R. Wang (2005) Antitumor effect of cytosine deaminase/5-fluorocytosine suicide gene therapy system mediated by Bifidobacterium infantison melanoma. Acta Pharmacol. Sin. 26: 629-634.
Fu, G. F., X. Li, Y. Y. Hou, Y. R. Fan, W. H. Liu, and G. X. Xu (2005) Bifidobacterium longumas an oral delivery system of endostatin for gene therapy on solid liver cancer. Cancer Gene Ther. 12: 133-140.
Xu, Y. F., L. P. Zhu, B. Hu, G. F. Fu, H. Y. Zhang, J. J. Wang, and G. X. Xu (2007) A new expression plasmid in Bifidobacterium longumas a delivery system of endostatin for cancer gene therapy. Cancer Gene Ther. 14: 151-157.
Long, R. T., W. S. Zeng, L. Y. Chen, J. Guo, Y. Z. Lin, Q. S. Huang, and S. Q. Luo (2010) Bifidobacteriumas an oral delivery carrier of oxyntomodulin for obesity therapy: inhibitory effects on food intake and body weight in overweight mice. Int. J. Obes (Lond). 34: 712-719.
Joint FAO/WHO (2001) Expert Consultation on "Evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria". pp. 1-32
Report of Joint FAO/WHO (2002) Working Group on "Drafting guide lines for the evaluation of probiotics in food".
Natural Health Products Directorate (2003) "Evidence for safety and efficacy of finished natural health products".
Notario, R., N. Leardini, N. Borda, T. Gambande, and H. Cerutti (2003) Hepatic abscess and bacteremia due to Lactobacillus rhamnosus. Rev. Argent. Microbiol. 35: 100-101.
Rautio, M., H. Jousimies-Somer, H. Kauma, I. Pietarinen, M. Saxelin, S. Tynkkynen, and M. Koskela (1999) Liver abscess due to a Lactobacillus rhamnosusstrain indistinguishable from L. rhamnosus strain GG. Clin. Infect. Dis. 28: 1159-1160.
Mackay, A. D., M. B. Taylor, C. C. Kibbler, and J. M. Hamilton-Miller (1999) Lactobacillus endocarditis caused by a probiotic organism. Clin. Microbiol. Infect 5: 290-292.
Munoz, P., E. Bouza, M. Cuenca-Estrella, J. M. Eiros, M. J. Perez, M. Sanchez-Somolinos, C. Rincon, J. Hortal, and T. Pelaez (2005) Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis. 40: 1625-1634.
Presterl, E., W. Kneifel, H. K. Mayer, M. Zehetgruber, A. Makristathis, and W. Graninger (2001) Endocarditis by Lactobacillus rhamnosusdue to yogurt ingestion? Scand. J. Infect. Dis. 33: 710-714.
Burkhardt, O., T. Kohnlein, M. Pletz, and T. Welte (2005) Saccharomyces boulardiiinduced sepsis: successful therapy with voriconazole after treatment failure with fluconazole. Scand. J. Infect Dis. 37: 69-72.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.